secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000950170-23-059024
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel reports CAN-2409 phase 2 interim data: 71.4% survival at 36 months vs 16.7% in borderline PDAC
--------------------------------------------------------------------------------

- Estimated overall survival rate 71.4% at 24 & 36 months for CAN-2409 arm vs 16.7% control in borderline resectable PDAC.
- Median overall survival not yet reached in CAN-2409 arm; control arm median OS was 12.5 months.
- Robust immune activation: dense aggregates of CD8+ granzyme B+ T cells, dendritic cells, and B cells in tumor.
- No dose-limiting toxicities or pancreatitis reported; multiple injections generally well tolerated.
- 5 of 7 CAN-2409 patients alive at data cutoff; two survived >45 months. Control: 1 of 6 alive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023059024/0000950170-23-059024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023059024/cadl-20231103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer